RAPT Therapeutics (NASDAQ:RAPT) announced its quarterly earnings results on Wednesday. The company reported ($12.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.15) by ($6.26), Bloomberg Earnings reports.
Shares of NASDAQ RAPT opened at $23.60 on Thursday. RAPT Therapeutics has a 12-month low of $11.85 and a 12-month high of $42.00.
Several analysts have issued reports on the stock. UBS Group upped their price target on shares of RAPT Therapeutics from $26.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Wells Fargo & Co assumed coverage on shares of RAPT Therapeutics in a report on Monday, November 25th. They issued an “outperform” rating and a $33.00 price target on the stock. Finally, BMO Capital Markets assumed coverage on shares of RAPT Therapeutics in a report on Monday, November 25th. They issued an “outperform” rating and a $35.00 price target on the stock.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.